



INFORMATION ONLY

Glassia Launch Update
 Customer Letter # 2024-04

2024-01-22

Dear Colleagues,

Canadian Blood Services is pleased to announce that Glassia (alpha-1 proteinase inhibitor [A1-PI]), manufactured by Takeda, will be available to be ordered from Canadian Blood Services on **February 29, 2024**. Please note that transfusion medicine laboratories may require additional time to make the product available for patients.

In Alberta, Glassia will be dispensed and delivered to patients by Bayshore Specialty Pharmacy as part of the pilot. It is expected that Glassia will be available through Bayshore Specialty Pharmacy on **March 18, 2024**.

Access to Glassia will be managed through Canadian Blood Services' Named Patient Contract process. Requests for Glassia can be submitted using the "Request for Patient Designated Plasma Protein and Related Products" form once it has been updated with the criteria. The form will specify that Glassia can be requested for adult patients with severe A1-PI deficiency and clinical evidence of emphysema who meet the following criteria*:

- The respirologist has confirmed the diagnosis of severe A1-PI deficiency and clinical evidence of emphysema and indicated that the patient would benefit from treatment with A1-PI product.
- **A1-PI deficiency, defined as serum A1-PI levels <11 µM/L or < 57 mg/dL** before start of the treatment, and**
- Clinical evidence of emphysema (FEV1 <80%), and
- Patients must be nonsmokers for at least 6 months.
- For patients who have not received a lung transplant.

*Criteria is based on recommendations from CADTH.

**The serum level included in the previous customer letter (2023-D31) has been corrected.

Key Product Highlights:

Product	Product Class	Route of Administration	Material Master Number	Vial size	Storage Temperature
Glassia	Alpha-1 Proteinase Inhibitor	Intravenous	1000109400	1000 mg / 50 mL	+2°C to +8°C



**Canadian
Blood
Services**

BLOOD
PLASMA
STEM CELLS
ORGANS
& TISSUES

1800 Alta Vista Drive
Ottawa ON
K1G 4J5
Canada

Please refer to the attached letter from Takeda for further details regarding the product. A Patient Support Program will be made available by the manufacturer.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the “Hospitals Services” section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Sylvain Grenier
Director, Plasma Protein and Related Products Formulary Program